Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belimumab - GlaxoSmithKline/MedImmune

Drug Profile

Belimumab - GlaxoSmithKline/MedImmune

Alternative Names: Anti-BLyS monoclonal antibody; Benlysta; BmAb; GSK1550188; HGS-1006; LSB; LymphoStat-B; monoclonal anti-BLyS

Latest Information Update: 11 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology; Human Genome Sciences
  • Developer Assistance Publique Hopitaux de Paris; Cancer Trials Australia; GlaxoSmithKline; Hospital for Special Surgery; Human Genome Sciences; North Shore-Long Island Jewish Health System; University of Alabama at Birmingham; University of Pennsylvania; University of Wisconsin-Madison; Washington University School of Medicine
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Systemic lupus erythematosus
  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis
  • Phase II/III Myositis
  • Phase II Emphysema; Membranous glomerulonephritis; Myasthenia gravis; Renal transplant rejection; Sjogren's syndrome; Systemic scleroderma
  • Phase I Graft-versus-host disease
  • No development reported Waldenstrom's macroglobulinaemia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 30 Oct 2019 GlaxoSmithKline plans a phase I trial for Systemic Lupus Erythematosus (In volunteers) in China in October 2019 (NCT04136145)
  • 29 Oct 2019 Phase-II clinical trials in Systemic lupus erythematosus (In children, In adolescents, Treatment-experienced) in Netherlands (SC) (EudraCT 2018-004645-16)
  • 29 Oct 2019 Registered for Systemic lupus erythematosus (Adjunctive treatment, In adolescents, In children, Treatment-experienced) in Norway, Liechtenstein, Iceland, European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top